What is tesamorelin? An approved drug being sold into the wrong market

Approved, and narrowly

Tesamorelin is unusual in the peptide conversation because it's genuinely approved. You'll see it as Egrifta, or under the development code TH9507.

Then you read what it's approved for, and the picture changes.

Excess abdominal fat in adults with HIV-associated lipodystrophy. That's the indication. Not weight loss. Not body composition. Not aging.

Our profile calls it a GHRH analog approved for excess belly fat in adults with that condition. We rate it high evidence with an established record, one of only four compounds in our research directory at that tier.

So the evidence is strong. The claim it supports is narrow.

Both are true, and the second is where almost every discussion of this drug goes wrong.

What the trials found, and the sentence that follows

Randomized trials found reductions in visceral adipose tissue in the labeled population.

That's a real result in a real population, measured properly against a comparison group.² It's why the approval exists.

Then our profile adds an unusually blunt rider: the effect should not be generalized to routine weight loss, bodybuilding, or healthy aging.

We don't write that line for most compounds. It's here because this is the case where the leap is most tempting and least supported.

The reasoning is simple. Lipodystrophy involves a particular pattern of fat redistribution, in a particular group of people, often tied to their treatment.

Fixing an abnormal pattern in that setting is not the same as removing ordinary belly fat from a healthy adult. Those aren't the same clinical target, and nothing has shown the effect carries across.

This is the narrowness point that runs through everything we publish, and tesamorelin is its sharpest case. An approval attaches to a molecule, a formulation, a group of patients, and a use.

Drop any one of those and you're outside what was shown.

How it works

Tesamorelin stimulates pituitary growth-hormone release and downstream IGF-1 through the GHRH receptor.

That puts it in the same mechanistic family as CJC-1295, which is worth noticing.

Same receptor, very different evidence positions. CJC-1295 raised growth hormone in small volunteer studies and never established a clinical benefit. Tesamorelin completed randomized trials measuring an actual outcome in a defined population and earned an approval.

The mechanism didn't decide which one got approved. The trials did. Two compounds pressing the same switch, one with an outcome behind it and one without, is about as clean an illustration as this topic offers of why mechanism isn't evidence. More on that in why evidence maturity beats online momentum.

17 vendors, one approval that doesn't travel

Here's the odd part.

Tesamorelin is listed by 17 vendors in our price market at $27.95 to $169.99 per package, as of the 25 July 2026 check.

That's more sellers than semaglutide, tirzepatide, and retatrutide combined.

So an approved drug for a narrow HIV-related use is stocked right across a research market. Its buyers are overwhelmingly not the people it was approved for.

The approval does not come with the vial. A research listing is not Egrifta, it hasn't been through the manufacturing and oversight an approved finished product carries, and it isn't authorized for human use.¹

What the approval does provide is something most research-market compounds lack entirely: a real body of trial evidence about the molecule. That's worth something when you're assessing the compound. It's worth nothing when you're assessing a package.

The dose data is the best we've seen

One genuinely positive finding, and it stands out.

Our testing ledger holds seven published lab records for tesamorelin.³ Measured against every compound with at least three records:

Five of seven tesamorelin vials landed within 5% of their labelled amount, with a median miss of 3.8%. Purity ran 99.04% to 99.82%.

Among compounds with more than three records, that's the tightest accuracy in our ledger. Compare it to the GLP-1 side, where tirzepatide misses by a median of 13.1%.

Seven records is still a small sample and can't characterise 17 vendors. Two of those seven also carry identical values under different vendor names, which is the shared-result pattern we document elsewhere.

Where tesamorelin sits

Genuinely approved, genuinely well evidenced. Not an experimental compound, and it deserves to be discussed differently from the unapproved ones.

Approved for one condition, with our own profile warning against stretching the effect to weight loss, bodybuilding, or aging.

Widely sold to people it wasn't approved for. The approval tells you about the molecule and nothing about the package.

Better documented on dose than anything else we track, on a still-small sample.

The frame worth keeping: strong evidence for a narrow claim is not weak evidence for a broad one. It's just evidence for the narrow claim.

Profile with graded outcomes and sources: tesamorelin.